Pricing talks afoot, courts continue to support Biden's IRA

4 March 2024
judge_court_law_legal_usa_large

In another legal blow for opponents of the Inflation Reduction Act (IRA), a federal judge has now rejected a bid from AstraZeneca (LSE: AZN) to prevent price negotiations on its diabetes med Farxiga (dapagliflozin).

Sold as Forxiga in Europe, the SGLT2 inhibitor was the company’s best-selling asset in 2023, bringing in nearly $6 billion in its approved indications of chronic kidney disease, heart failure and type 2 diabetes.

The IRA allows administrators at Medicare to negotiate certain drug prices with manufacturers, for the first time, with the goal of reducing prices for patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical